10-Q Filing

TEVA PHARMACEUTICAL INDUSTRIES LTD CIK: 818686 Q1 2021

Filing Information

Form Type	10-Q
Accession Number	`0001193125-21-136842`
Period End Date	20210331
Filing Date	20210428
Fiscal Year	2021
Fiscal Period	Q1
XBRL Instance	d26234d10q_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 86 Income Statement 44 Cash Flow Statement 50 Stockholders Equity 16 Comprehensive Income 14

Balance Sheet 86 line items

Line Item	Tag	Value	Unit	Period
Allowance for credit losses	`AllowanceForDoubtfulAccountsReceivableCurrent`	$126.00M	USD	Point-in-time
Allowance for credit losses	`AllowanceForDoubtfulAccountsReceivableCurrent`	$119.00M	USD	Point-in-time
Common stock, par or stated value per share	`CommonStockParOrStatedValuePerShare`	0.10	CHF	Point-in-time
Common stock, par or stated value per share	`CommonStockParOrStatedValuePerShare`	0.10	CHF	Point-in-time
Ordinary shares, authorized	`CommonStockSharesAuthorized`	2.50B	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$1.74B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$2.18B	USD	Point-in-time
Ordinary shares, authorized	`CommonStockSharesAuthorized`	2.50B	shares	Point-in-time
Accounts receivables, net of allowance for credit losses of $119 million and $126 million as of March 31, 2021 and December 31, 2020	`AccountsReceivableNetCurrent`	$4.57B	USD	Point-in-time
Ordinary shares, issued	`CommonStockSharesIssued`	1.21B	shares	Point-in-time
Ordinary shares, issued	`CommonStockSharesIssued`	1.20B	shares	Point-in-time
Accounts receivables, net of allowance for credit losses of $119 million and $126 million as of March 31, 2021 and December 31, 2020	`AccountsReceivableNetCurrent`	$4.58B	USD	Point-in-time
Inventories	`InventoryNet`	$4.40B	USD	Point-in-time
Inventories	`InventoryNet`	$4.41B	USD	Point-in-time
Treasury shares	`TreasuryStockShares`	106.00M	shares	Point-in-time
Treasury shares	`TreasuryStockShares`	106.00M	shares	Point-in-time
Prepaid expenses	`PrepaidExpenseCurrent`	$942.00M	USD	Point-in-time
Prepaid expenses	`PrepaidExpenseCurrent`	$945.00M	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$710.00M	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$652.00M	USD	Point-in-time
Assets held for sale	`AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent`	$189.00M	USD	Point-in-time
Assets held for sale	`AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent`	$87.00M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$12.40B	USD	Point-in-time
Total current assets	`AssetsCurrent`	$13.01B	USD	Point-in-time
Deferred income taxes	`DeferredIncomeTaxAssetsNet`	$691.00M	USD	Point-in-time
Deferred income taxes	`DeferredIncomeTaxAssetsNet`	$695.00M	USD	Point-in-time
Other non-current assets	`OtherAssetsNoncurrent`	$538.00M	USD	Point-in-time
Other non-current assets	`OtherAssetsNoncurrent`	$524.00M	USD	Point-in-time
Property, plant and equipment, net	`PropertyPlantAndEquipmentNet`	$6.11B	USD	Point-in-time
Property, plant and equipment, net	`PropertyPlantAndEquipmentNet`	$6.30B	USD	Point-in-time
Operating lease right-of-use assets	`OperatingLeaseRightOfUseAsset`	$529.00M	USD	Point-in-time
Operating lease right-of-use assets	`OperatingLeaseRightOfUseAsset`	$559.00M	USD	Point-in-time
Identifiable intangible assets, net	`FiniteLivedIntangibleAssetsNet`	$8.92B	USD	Point-in-time
Identifiable intangible assets, net	`FiniteLivedIntangibleAssetsNet`	$8.45B	USD	Point-in-time
Goodwill	`Goodwill`	$20.62B	USD	Point-in-time
Goodwill	`Goodwill`	$20.30B	USD	Point-in-time
Total assets	`Assets`	$49.00B	USD	Point-in-time
Total assets	`Assets`	$50.64B	USD	Point-in-time
Short-term debt	`DebtCurrent`	$2.70B	USD	Point-in-time
Short-term debt	`DebtCurrent`	$3.19B	USD	Point-in-time
Sales reserves and allowances	`SalesReservesAndAllowances`	$4.58B	USD	Point-in-time
Sales reserves and allowances	`SalesReservesAndAllowances`	$4.82B	USD	Point-in-time
Accounts payables	`AccountsPayableTradeCurrent`	$1.76B	USD	Point-in-time
Accounts payables	`AccountsPayableTradeCurrent`	$1.69B	USD	Point-in-time
Employee-related obligations	`EmployeeRelatedLiabilitiesCurrent`	$526.00M	USD	Point-in-time
Employee-related obligations	`EmployeeRelatedLiabilitiesCurrent`	$685.00M	USD	Point-in-time
Accrued expenses	`AccruedExpenses`	$1.85B	USD	Point-in-time
Accrued expenses	`AccruedExpenses`	$1.78B	USD	Point-in-time
Other current liabilities	`OtherLiabilitiesCurrent`	$933.00M	USD	Point-in-time
Other current liabilities	`OtherLiabilitiesCurrent`	$739.00M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$12.09B	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$13.16B	USD	Point-in-time
Deferred income taxes	`DeferredTaxAndOtherLiabilitiesNoncurrent`	$964.00M	USD	Point-in-time
Deferred income taxes	`DeferredTaxAndOtherLiabilitiesNoncurrent`	$991.00M	USD	Point-in-time
Other taxes and long-term liabilities	`OtherLiabilitiesNoncurrent`	$2.24B	USD	Point-in-time
Other taxes and long-term liabilities	`OtherLiabilitiesNoncurrent`	$2.22B	USD	Point-in-time
Senior notes and loans	`LongTermNotesAndLoans`	$22.29B	USD	Point-in-time
Senior notes and loans	`LongTermNotesAndLoans`	$22.73B	USD	Point-in-time
Operating lease liabilities	`OperatingLeaseLiabilityNoncurrent`	$479.00M	USD	Point-in-time
Operating lease liabilities	`OperatingLeaseLiabilityNoncurrent`	$441.00M	USD	Point-in-time
Total long-term liabilities	`LiabilitiesNoncurrent`	$26.41B	USD	Point-in-time
Total long-term liabilities	`LiabilitiesNoncurrent`	$25.94B	USD	Point-in-time
Commitments and contingencies, see note 10	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies, see note 10	`CommitmentsAndContingencies`	-	USD	Point-in-time
Total liabilities	`Liabilities`	$39.58B	USD	Point-in-time
Total liabilities	`Liabilities`	$38.03B	USD	Point-in-time
Ordinary shares of NIS 0.10 par value per share; March 31, 2021 and December 31, 2020: authorized 2,495 million shares; issued 1,208 million shares and 1,202 million shares, respectively	`CommonStockValue`	$57.00M	USD	Point-in-time
Ordinary shares of NIS 0.10 par value per share; March 31, 2021 and December 31, 2020: authorized 2,495 million shares; issued 1,208 million shares and 1,202 million shares, respectively	`CommonStockValue`	$57.00M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$27.44B	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$27.47B	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-10.95B	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-10.87B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-2.53B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-2.40B	USD	Point-in-time
Treasury shares as of March 31, 2021 and December 31, 2020 106 million ordinary shares	`TreasuryStockValue`	$4.13B	USD	Point-in-time
Treasury shares as of March 31, 2021 and December 31, 2020 106 million ordinary shares	`TreasuryStockValue`	$4.13B	USD	Point-in-time
Stockholders' equity attributable to Teva shareholders	`StockholdersEquity`	$10.03B	USD	Point-in-time
Stockholders' equity attributable to Teva shareholders	`StockholdersEquity`	$10.00B	USD	Point-in-time
Non-controlling interests	`MinorityInterest`	$975.00M	USD	Point-in-time
Non-controlling interests	`MinorityInterest`	$1.03B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$11.06B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$15.06B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$10.97B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$14.59B	USD	Point-in-time
Total liabilities and equity	`LiabilitiesAndStockholdersEquity`	$50.64B	USD	Point-in-time
Total liabilities and equity	`LiabilitiesAndStockholdersEquity`	$49.00B	USD	Point-in-time

Income Statement 44 line items

Line Item	Tag	Value	Unit	Period
Net revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$3.98B	USD	1 Quarter
Net revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$4.36B	USD	1 Quarter
Cost of sales	`CostOfGoodsAndServicesSold`	$2.10B	USD	1 Quarter
Cost of sales	`CostOfGoodsAndServicesSold`	$2.29B	USD	1 Quarter
Gross profit	`GrossProfit`	$1.88B	USD	1 Quarter
Gross profit	`GrossProfit`	$2.06B	USD	1 Quarter
Research and development expenses	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$254.00M	USD	1 Quarter
Research and development expenses	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$221.00M	USD	1 Quarter
Selling and marketing expenses	`SellingAndMarketingExpense`	$613.00M	USD	1 Quarter
Selling and marketing expenses	`SellingAndMarketingExpense`	$585.00M	USD	1 Quarter
General and administrative expenses	`GeneralAndAdministrativeExpense`	$304.00M	USD	1 Quarter
General and administrative expenses	`GeneralAndAdministrativeExpense`	$290.00M	USD	1 Quarter
Intangible assets impairments	`IntangibleAssetsImpairments`	$649.00M	USD	1 Quarter
Intangible assets impairments	`IntangibleAssetsImpairments`	$79.00M	USD	1 Quarter
Other assets impairments, restructuring and other items	`ImpairmentsRestructuringAndOthers`	$121.00M	USD	1 Quarter
Other assets impairments, restructuring and other items	`ImpairmentsRestructuringAndOthers`	$137.00M	USD	1 Quarter
Legal settlements and loss contingencies	`LegalSettlementsAndLossContingencies`	$104.00M	USD	1 Quarter
Legal settlements and loss contingencies	`LegalSettlementsAndLossContingencies`	$-25.00M	USD	1 Quarter
Other income	`OtherOperatingIncomeExpenseNet`	$5.00M	USD	1 Quarter
Other income	`OtherOperatingIncomeExpenseNet`	$13.00M	USD	1 Quarter
Operating (loss) income	`OperatingIncomeLoss`	$434.00M	USD	1 Quarter
Operating (loss) income	`OperatingIncomeLoss`	$191.00M	USD	1 Quarter
Financial expenses, net	`NonoperatingIncomeExpense`	$-224.00M	USD	1 Quarter
Financial expenses, net	`NonoperatingIncomeExpense`	$-290.00M	USD	1 Quarter
Income (loss) before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$144.00M	USD	1 Quarter
Income (loss) before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-33.00M	USD	1 Quarter
Income taxes (benefit)	`IncomeTaxExpenseBenefit`	$62.00M	USD	1 Quarter
Income taxes (benefit)	`IncomeTaxExpenseBenefit`	$-59.00M	USD	1 Quarter
Share in (profits) losses of associated companies, net	`IncomeLossFromEquityMethodInvestments`	$3.00M	USD	1 Quarter
Share in (profits) losses of associated companies, net	`IncomeLossFromEquityMethodInvestments`	$-1.00M	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$25.00M	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$84.00M	USD	1 Quarter
Net income (loss) attributable to non-controlling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$7.00M	USD	1 Quarter
Net income (loss) attributable to non-controlling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$-44.00M	USD	1 Quarter
Net income (loss) attributable to Teva	`NetIncomeLoss`	$69.00M	USD	1 Quarter
Net income (loss) attributable to Teva	`NetIncomeLoss`	$77.00M	USD	1 Quarter
Basic	`EarningsPerShareBasic`	$0.06	USD	1 Quarter
Basic	`EarningsPerShareBasic`	$0.07	USD	1 Quarter
Diluted	`EarningsPerShareDiluted`	$0.07	USD	1 Quarter
Diluted	`EarningsPerShareDiluted`	$0.06	USD	1 Quarter
Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	1.09B	shares	1 Quarter
Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	1.10B	shares	1 Quarter
Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	1.11B	shares	1 Quarter
Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	1.10B	shares	1 Quarter

Cash Flow Statement 50 line items

Line Item	Tag	Value	Unit	Period
Net income (loss)	`ProfitLoss`	$25.00M	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$84.00M	USD	1 Quarter
Depreciation and amortization	`DepreciationAndAmortization`	$376.00M	USD	1 Quarter
Depreciation and amortization	`DepreciationAndAmortization`	$399.00M	USD	1 Quarter
Impairment of long-lived assets and assets held for sale	`AssetImpairmentCharges`	$724.00M	USD	1 Quarter
Impairment of long-lived assets and assets held for sale	`AssetImpairmentCharges`	$127.00M	USD	1 Quarter
Net change in operating assets and liabilities	`IncreaseDecreaseInOperatingCapital`	$666.00M	USD	1 Quarter
Net change in operating assets and liabilities	`IncreaseDecreaseInOperatingCapital`	$1.08B	USD	1 Quarter
Deferred income taxes net and uncertain tax positions	`DeferredIncomeTaxesNetAndUncertainTaxPositions`	$-11.00M	USD	1 Quarter
Deferred income taxes net and uncertain tax positions	`DeferredIncomeTaxesNetAndUncertainTaxPositions`	$-233.00M	USD	1 Quarter
Stock-based compensation	`ShareBasedCompensation`	$30.00M	USD	1 Quarter
Stock-based compensation	`ShareBasedCompensation`	$31.00M	USD	1 Quarter
Net loss (gain) from investments and from sale of long lived assets	`ProfitFromSaleOfLongLivedAssetsAndInvestment`	$-24.00M	USD	1 Quarter
Net loss (gain) from investments and from sale of long lived assets	`ProfitFromSaleOfLongLivedAssetsAndInvestment`	$-74.00M	USD	1 Quarter
Other items	`OtherOperatingActivitiesCashFlowStatement`	$2.00M	USD	1 Quarter
Other items	`OtherOperatingActivitiesCashFlowStatement`	$-10.00M	USD	1 Quarter
Net cash provided by (used in) operating activities	`NetCashProvidedByUsedInOperatingActivities`	$305.00M	USD	1 Quarter
Net cash provided by (used in) operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-405.00M	USD	1 Quarter
Beneficial interest collected in exchange for securitized accounts receivables	`ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables`	$368.00M	USD	1 Quarter
Beneficial interest collected in exchange for securitized accounts receivables	`ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables`	$476.00M	USD	1 Quarter
Purchases of property, plant and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$128.00M	USD	1 Quarter
Purchases of property, plant and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$150.00M	USD	1 Quarter
Proceeds from sale of business and long lived assets	`ProceedsFromDivestitureOfBusinesses`	$6.00M	USD	1 Quarter
Proceeds from sale of business and long lived assets	`ProceedsFromDivestitureOfBusinesses`	$138.00M	USD	1 Quarter
Proceeds from sale of investments and other investing activities	`ProceedsFromSaleMaturityAndCollectionsOfInvestments`	$44.00M	USD	1 Quarter
Proceeds from sale of investments and other investing activities	`ProceedsFromSaleMaturityAndCollectionsOfInvestments`	$6.00M	USD	1 Quarter
Net cash provided by investing activities	`NetCashProvidedByUsedInInvestingActivities`	$252.00M	USD	1 Quarter
Net cash provided by investing activities	`NetCashProvidedByUsedInInvestingActivities`	$508.00M	USD	1 Quarter
Repayment of senior notes and loans and other long-term liabilities	`RepaymentsOfLongTermDebt`	-	USD	1 Quarter
Repayment of senior notes and loans and other long-term liabilities	`RepaymentsOfLongTermDebt`	$700.00M	USD	1 Quarter
Redemption of convertible senior notes	`RepaymentOfConvertibleDebt`	$491.00M	USD	1 Quarter
Redemption of convertible senior notes	`RepaymentOfConvertibleDebt`	-	USD	1 Quarter
Other financing activities	`ProceedsFromPaymentsForOtherFinancingActivities`	$-2.00M	USD	1 Quarter
Other financing activities	`ProceedsFromPaymentsForOtherFinancingActivities`	-	USD	1 Quarter
Net cash used in financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-700.00M	USD	1 Quarter
Net cash used in financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-493.00M	USD	1 Quarter
Translation adjustment on cash and cash equivalents	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$-44.00M	USD	1 Quarter
Translation adjustment on cash and cash equivalents	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$-28.00M	USD	1 Quarter
Net change in cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-171.00M	USD	1 Quarter
Net change in cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-434.00M	USD	1 Quarter
Balance of cash and cash equivalents at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.80B	USD	Point-in-time
Balance of cash and cash equivalents at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.98B	USD	Point-in-time
Balance of cash and cash equivalents at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.74B	USD	Point-in-time
Balance of cash and cash equivalents at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$2.18B	USD	Point-in-time
Balance of cash and cash equivalents at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.80B	USD	Point-in-time
Balance of cash and cash equivalents at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.98B	USD	Point-in-time
Balance of cash and cash equivalents at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.74B	USD	Point-in-time
Balance of cash and cash equivalents at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$2.18B	USD	Point-in-time
Beneficial interest obtained in exchange for securitized accounts receivables	`BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables`	$488.00M	USD	Point-in-time
Beneficial interest obtained in exchange for securitized accounts receivables	`BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables`	$375.00M	USD	Point-in-time

Stockholders Equity 16 line items

Line Item	Tag	Value	Unit	Period
Beginning balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$11.06B	USD	Point-in-time
Beginning balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$15.06B	USD	Point-in-time
Beginning balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$10.97B	USD	Point-in-time
Beginning balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$14.59B	USD	Point-in-time
Net Income (loss)	`ProfitLoss`	$25.00M	USD	1 Quarter
Net Income (loss)	`ProfitLoss`	$84.00M	USD	1 Quarter
Other Comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$-530.00M	USD	1 Quarter
Other Comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$-201.00M	USD	1 Quarter
Issuance of Shares, value	`StockIssuedDuringPeriodValueNewIssues`	-	USD	1 Quarter
Issuance of Shares, value	`StockIssuedDuringPeriodValueNewIssues`	-	USD	1 Quarter
Stock-based compensation expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$30.00M	USD	1 Quarter
Stock-based compensation expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$31.00M	USD	1 Quarter
Ending balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$11.06B	USD	Point-in-time
Ending balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$15.06B	USD	Point-in-time
Ending balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$10.97B	USD	Point-in-time
Ending balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$14.59B	USD	Point-in-time

Comprehensive Income 14 line items

Line Item	Tag	Value	Unit	Period
Net income (loss)	`ProfitLoss`	$25.00M	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$84.00M	USD	1 Quarter
Currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-560.00M	USD	1 Quarter
Currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-208.00M	USD	1 Quarter
Unrealized gain (loss) from derivative financial instruments, net	`OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax`	$-7.00M	USD	1 Quarter
Unrealized gain (loss) from derivative financial instruments, net	`OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax`	$-30.00M	USD	1 Quarter
Total other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$-530.00M	USD	1 Quarter
Total other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$-201.00M	USD	1 Quarter
Total comprehensive income (loss)	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-117.00M	USD	1 Quarter
Total comprehensive income (loss)	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-505.00M	USD	1 Quarter
Comprehensive income (loss) attributable to non-controlling interests	`ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest`	$-60.00M	USD	1 Quarter
Comprehensive income (loss) attributable to non-controlling interests	`ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest`	$-34.00M	USD	1 Quarter
Comprehensive income (loss) attributable to Teva	`ComprehensiveIncomeNetOfTax`	$-471.00M	USD	1 Quarter
Comprehensive income (loss) attributable to Teva	`ComprehensiveIncomeNetOfTax`	$-57.00M	USD	1 Quarter

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.